礼来公布对比试验结果：Zepbound减肥效果好于诺和诺德Wegovy

市场资讯12-05

（来源：财联社）　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。　　受此消息影响，礼来美股盘前涨近2%。　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%（约50磅），而使用Wegovy的患者体重减轻了13.7%（约33磅）。　　这项试验招募了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2489711104?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-05 01:00","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2489711104","market":"sg","top_or_hot":-1,"title":"礼来公布对比试验结果：Zepbound减肥效果好于诺和诺德Wegovy","media":"市场资讯","content":"<div>\n<p>（来源：财联社）\n　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。\n　　受此消息影响，礼来美股盘前涨近2%。\n　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%（约50磅），而使用Wegovy的患者体重减轻了13.7%（约33磅）。\n　　这项试验招募了...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-12-05/doc-incyirkf3557420.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来公布对比试验结果：Zepbound减肥效果好于诺和诺德Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来公布对比试验结果：Zepbound减肥效果好于诺和诺德Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 01:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2024-12-05/doc-incyirkf3557420.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（来源：财联社）\n　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。\n　　受此消息影响，礼来美股盘前涨近2%。\n　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%（约50磅），而使用Wegovy的患者体重减轻了13.7%（约33磅）。\n　　这项试验招募了...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-12-05/doc-incyirkf3557420.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0198837287.USD","symbol_name":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-12-05/doc-incyirkf3557420.shtml","article_id":"2489711104","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489711104","pubTimestamp":1733331600,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%，而使用Wegovy的患者体重减轻了13.7%。　　礼来公司表示，在对比试验中，Zepbound的相对减重效果比Wegovy高出47%。　　对礼来而言，Zepbound的减重效果上更突出或许能帮助其在减肥药市场领先于诺和诺德。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4532":"文艺复兴科技持仓","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","BK4599":"减肥药","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4588":"碎股","LLY":"礼来","LU0079474960.USD":"联博美国增长基金A","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","NVO":"诺和诺德","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Eli Lilly announces comparative trial results: Zepbound weight loss effect is better than Novo Nordisk Wegovy","themeId":"e266721f8746851af3f56ae2b1743ae8","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":1},"content_text":"（来源：财联社）\n　　美国制药巨头礼来公司周三宣布，在一次对比试验中，其减肥药物Zepbound的减重效果高于竞争对手诺和诺德的同类药物Wegovy。\n　　受此消息影响，礼来美股盘前涨近2%。\n　　这项对比试验由礼来赞助，其结果显示，使用Zepbound的患者在经过72周的治疗后体重平均减轻了20.2%（约50磅），而使用Wegovy的患者体重减轻了13.7%（约33磅）。\n　　这项试验招募了751名患有肥胖症或超重的患者，这些患者均没有糖尿病。参与者分成两组，每周注射其中一种药物，剂量逐步增加至最大耐受剂量。\n　　礼来公司表示，在对比试验中，Zepbound的相对减重效果比Wegovy高出47%。该公司还称，使用Zepbound的人中超过31%的人减掉了至少四分之一的体重，而使用Wegovy的人中只有约16%的人减掉了这么多的体重。\n　　礼来仍在评估试验结果，该公司表示，计划将其发表在同行评审的期刊上，并于明年在医学会议上发布。\n　　这项试验验证了早些时候的一项研究。今年7月公布的一项研究显示，礼来的Mounjaro能比诺和诺德的Ozempic更快、更有效地减肥。\n　　Mounjaro和Zepbound拥有相同的活性成分，即替尔泊肽。而Ozempic和Wegovy的活性成本也是相同的，即司美格鲁肽。\n　　这四种药均属于GLP-1（胰高血糖素样肽-1）药物，不同的地方在于，Mounjaro和Ozempic被批准用于治疗糖尿病，而Zepbound和Wegovy则专注于减肥。\n　　诺和诺德周三表示，该公司的临床试验显示，与安慰剂相比，Wegovy可将心脏病发作、中风及其他主要心血管疾病的风险降低20%，且这一变化与体重变化无关。\n　　“我们知道，治疗这种被误解的疾病不仅仅是体重秤上的数字，”诺和诺德称。\n　　对礼来而言，Zepbound的减重效果上更突出或许能帮助其在减肥药市场领先于诺和诺德。有分析师预计，到2030年，全球减肥药市场的年销售额可能会增加到1300亿美元左右。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：丁文武","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489711104"}